Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy

Su Li; Qinghua Wang; Zhen Jia; Mengting Da; Jiuda Zhao; Rui Yang; Daozhen Chen

doi:10.1016/j.heliyon.2023.e20407

Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy

Heliyon. 2023 Sep 25;9(10):e20407. doi: 10.1016/j.heliyon.2023.e20407. eCollection 2023 Oct.

Authors

Su Li¹, Qinghua Wang², Zhen Jia³, Mengting Da⁴, Jiuda Zhao⁴, Rui Yang¹, Daozhen Chen^{1

3}

Affiliations

¹ Research Institute for Reproductive Health and Genetic Diseases, The Affiliated Wuxi Maternity and Child Health Hospital of Nanjing Medical University, Wuxi, 214002, China.
² Wuxi Maternal and Child Health Hospital, Wuxi School of Medicine, Jiangnan University, Jiangsu, 214002, China.
³ Department of Obstetrics and Gynecology, Haidong No. 2 People's Hospital, Haidong, 810699, China.
⁴ Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining, 810001, China.

Abstract

Glucose oxidase (GOx) can specifically catalyze the conversion of β-d-glucose into gluconic acid and hydrogen peroxide (H₂O₂) in the presence of oxygen, making it promising for tumor starvation therapy and oxidative therapy. However, GOx's immunogenicity, poor in vivo stability, short half-life, and potential systemic toxicity, limit its application in cancer therapy. Nanocarriers are capable of improving the pharmacological properties of therapeutic drugs (e.g. stability, circulating half-life, and tumor accumulation) and lower toxicity, hence resolving GOx issues and enhancing its efficacy. Although the application of targeted nanocarriers based on GOx has recently flourished, this field has not yet been reviewed and evaluated. Herein, we initially examined the mechanism of GOx-based nanocarriers for enhanced tumor therapy. Also, we present a comprehensive and up-to-date review that highlights GOx-based nanocarriers for tumor targeting therapy. This review expands on GOx-based nano-targeted combination therapies from both passive and active targeting perspectives, meanwhile, active targeting is further classified into ligand-mediated targeting and physical-mediated targeting. Furthermore, this review also emphasizes the present challenges and promising advancements.

Keywords: Cancer; Glucose oxidase; Nanocarriers; Targeted therapy.

Publication types

Review